Pfizer Reports Decline in Q3 Revenue, Announces Acquisition of Metsera

Pfizer Inc. reported a decline in financial performance for the third quarter and first nine months of 2025, as detailed in its latest 10-Q filing. Total revenues for the third quarter reached $16.7 billion, a decrease of 6% from $17.7 billion in the same period last year. This decline was attributed to lower sales of key products, particularly Paxlovid and Comirnaty, which were impacted by reduced COVID-19 infection rates and a narrower vaccination recommendation. For the first nine months, total revenues also fell by 2% to $45.0 billion, primarily driven by a decrease in Paxlovid sales, partially offset by growth in other products like the Vyndaqel family and Eliquis.

In terms of profitability, Pfizer's net income attributable to common shareholders for the third quarter was $3.5 billion, down from $4.5 billion a year earlier, while for the first nine months, it increased to $9.4 billion from $7.6 billion. The increase in net income for the nine-month period was largely due to reduced costs in sales, administrative expenses, and research and development, despite higher acquired in-process research and development expenses. Earnings per share for the third quarter were $0.62, compared to $0.79 in the prior year, while for the nine months, it rose to $1.66 from $1.35.

Strategically, Pfizer has been active in business development, announcing a definitive agreement to acquire Metsera, a clinical-stage biopharmaceutical company, for approximately $4.9 billion. This acquisition aims to enhance Pfizer's capabilities in treating obesity and cardiometabolic diseases. Additionally, Pfizer has entered into funding arrangements with Abingworth and Blackstone to co-fund research and development costs for specific treatments, which are expected to reduce R&D expenses over time.

Operationally, Pfizer's total assets decreased to $208.7 billion as of September 28, 2025, down from $213.4 billion at the end of 2024. The company reported a significant increase in cash and cash equivalents, which rose to $1.3 billion, while trade accounts receivable also increased to $14.3 billion. The company continues to focus on improving operational efficiency and margin expansion, with ongoing restructuring programs aimed at realigning costs with long-term revenue expectations.

Looking ahead, Pfizer anticipates continued challenges in the market, particularly with the ongoing impact of COVID-19 on product demand and pricing pressures from government regulations. The company is also preparing for the implementation of the Inflation Reduction Act, which may affect pricing and reimbursement for its products. Despite these challenges, Pfizer remains committed to its strategic priorities, including enhancing R&D productivity and optimizing capital allocation, as it navigates the evolving biopharmaceutical landscape.